Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression

Published:2022-06 Issue: Volume:Volume 14 Page:1891-1902
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Xu Ziyi^ORCID,Teng Fei,Hao Xuezhi,Li Junling,Xing Puyuan

Publisher

Informa UK Limited

Subject

Oncology

Reference42 articles.

1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

2. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

3. Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

4. EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

5. Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3